Details of the Drug Formulations

General Information of Drug (ID: DM26CQR)

Drug Name
Larotrectinib Drug Info
Synonyms
UNII-PF9462I9HX; PF9462I9HX; ARRY 470; Larotrectinib [USAN:INN]; GTPL8909; SCHEMBL2241012; NYNZQNWKBKUAII-KBXCAEBGSA-N; BDBM136597; ZINC118399834; AKOS027338709; example 14 [US8865698 B2]; CS-5722; HY-12866; AS-35231; J3.628.138C; US8865698, 14; ARRY470; ARRY-470
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1]
Cross-matching ID
PubChem CID
46188928
CAS Number
1223403-58-4
TTD ID
D07TOK
ACDINA ID
D01197

Full List of Drug Formulations Containing This Drug

Larotrectinib 20 mg/ml solution
Company Formulation ID FDA Description
Bayer Healthcare Pharmaceuticals ; Loxo Oncology; F24272 Purified Water; Hydroxypropyl Betadex; Sucrose; Glycerin; Sorbitol; Citric Acid; Sodium Phosphate; Sodium Citrate Dihydrate; Propylene Glycol; Flavoring; Methylparaben; Potassium Sorbate
------------------------------------------------------------------------------------
Larotrectinib 100 mg capsule
Company Formulation ID FDA Description
Bayer Healthcare Pharmaceuticals ; Loxo Oncology F24313 Gelatin; Titanium Dioxide; Edible Ink
------------------------------------------------------------------------------------
Larotrectinib 25 mg capsule
Company Formulation ID FDA Description
Bayer Healthcare Pharmaceuticals ; Loxo Oncology F24371 Gelatin; Titanium Dioxide; Edible Ink
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)